Table 2.

Myocarditis Events 21 Days After Second Dose and Rate/Million Doses by Vaccine Product, Sex, and Age

	Pfizer						Moderna
	Total		Men		Women		Total		Men		Women
	N	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)	N	Rate (95% CI)	n	Rate (95% CI)	n	Rate (95% CI)
Total	28	12.59 (8.37-18.20)	19	18.47 (11.12-28.85)	9	7.53 (3.44-14.29)	31	35.55 (24.15-50.46)	25	58.32 (37.74-86.08)	6	13.53 (4.96-29.46)
Age, y
18-29	12	30.18 (15.59-52.72)	11	58.05 (28.98-103.87)	1	4.80 (0.12-26.77)	22	149.48 (93.67-226.31)	20	269.57 (164.66-416.33)	2	27.40 (3.32-98.98)
30-39	2	5.39 (0.65-19.50)	2	11.39 (1.38-41.15)	0	0 (—)	6	41.08 (15.07-89.42)	4	53.90 (14.68-138.01)	2	27.84 (3.37-100.58)
40-49	3	9.43 (1.94-27.55)	2	13.79 (1.67-49.83)	1	5.77 (1.38-41.15)	1	8.33 (0.21-46.44)	1	16.84 (0.42-93.82)	0	0 (—)
≥50	11	9.67 (4.83-17.31)	4	7.71 (2.10-19.75)	7	11.31 (4.55-23.31)	2	4.36 (0.52-15.74)	0	0 (—)	2	8.41 (1.02-30.37)